The Hetero Ring Is Three-membered Patents (Class 514/475)
  • TIGLIEN-3-ONE DERIVATIVES
    Publication number: 20140155479
    Abstract: The present invention relates to tiglien-3-one compounds and their use in methods of treating or preventing protozoal infections, bacterial infections, parasitic infections and cell proliferative disorders. The tiglien-3-one compounds are also used in methods of controlling pests in humans, animals, plants and the environment.
    Type: Application
    Filed: November 20, 2013
    Publication date: June 5, 2014
    Applicant: QBiotics Limited
    Inventors: Paul Warren Reddell, Victoria Anne Gordon
  • USE OF CATHEPSIN K INHIBITION FOR THE TREATMENT AND/OR PROPHYLAXIS OF PULMONARY HYPERTENSION AND/OR HEART FAILURE
    Publication number: 20140155383
    Abstract: The present invention relates to the use of cathepsin K and/or cathepsin S inhibitors in a method for the treatment and/or prophylaxis of pulmonary hypertension and/or heart failure.
    Type: Application
    Filed: May 11, 2012
    Publication date: June 5, 2014
    Applicant: BAYER INTELLECTUAL PROPERTY GMBH
    Inventors: Stefan Golz, Martina Delbeck, Heinrich Meier, Andreas Geerts, Thomas Mondritzki, Hubert Trübel
  • Inhibitors of carnitin-palmitoyl-tranferase-1 for the treatment and prevention of disorders caused by delipidation of neural tissue
    Patent number: 8741949
    Abstract: Carnitin-Palmitoyl-Transferase-1 (CPT-1) inhibitor for use in treating and/or preventing disorders caused by delipidation of neural tissue.
    Type: Grant
    Filed: June 25, 2009
    Date of Patent: June 3, 2014
    Assignee: Meta-IQ ApS
    Inventor: Josephus Dirk Nieland
  • METHODS OF TREATING GIARDIASIS
    Publication number: 20140148398
    Abstract: Compounds useful for the treatment of giardiasis are described.
    Type: Application
    Filed: October 12, 2011
    Publication date: May 29, 2014
    Applicants: The United States of America, as represented by the Secretary, Dept. of Health and Human Service, UNIVERSITY OF MARYLAND, COLLEGE PARK
    Inventors: Wei Zheng, Catherine Chen, Juan Jose Marugan, Noel Southall, Christopher P. Austin, Andrey Galkin, Liudmila Kulakova, Osnat Herzberg
  • Crystalline solids of a MetAP-2 inhibitor and methods of making and using same
    Patent number: 8735447
    Abstract: The disclosure is in part directed to crystalline forms of 6-O-(4-dimethylaminoethoxy)cinnamoyl fumagillol and variants thereof.
    Type: Grant
    Filed: November 16, 2012
    Date of Patent: May 27, 2014
    Assignee: Zafgen, Inc.
    Inventors: Thomas Crawford, Hayley A. Reece
  • Compounds for enzyme inhibition
    Patent number: 8735441
    Abstract: One aspect of the invention relates to inhibitors that preferentially inhibit immunoproteasome activity over constitutive proteasome activity. In certain embodiments, the invention relates to the treatment of immune related diseases, comprising administering a compound of the invention. In certain embodiments, the invention relates to the treatment of cancer, comprising administering a compound of the invention.
    Type: Grant
    Filed: October 5, 2012
    Date of Patent: May 27, 2014
    Assignee: Onyx Therapeutics, Inc.
    Inventors: Kevin D. Shenk, Francesco Parlati, Han-jie Zhou, Catherine Sylvain, Mark S. Smyth, Mark K. Bennett, Guy J. Laidig
  • Substituted cyclohexylidene-ethylidene-octahydro-indene compounds
    Patent number: 8716334
    Abstract: Novel substituted cyclohexylidene-ethylidene-octahydro-indene compounds and compositions comprising the same are described. The compounds exhibit profound anti-proliferative effects, in comparison to other compounds known for their anti-cancer and anti-hyperproliferative ability. Methods of use of such compounds and compositions are described for treating a variety of cancers, inflammatory and other hyperproliferative diseases and disorders.
    Type: Grant
    Filed: June 16, 2009
    Date of Patent: May 6, 2014
    Assignee: Ben Gurion University of the Negev Research and Development Authority
    Inventors: Shimon Ben Shabat, Amnou Sintov
  • NOTCH mutations leading to increased receptor signaling
    Patent number: 8716233
    Abstract: The present invention is based upon the identification of regions within the NOTCH-1 receptor that, when mutated, lead to increase receptor signaling. The mutations are associated with uncontrolled cellular growth and this growth may be arrested using agents that interfere with NOTCH-1 activity, such as inhibitors of gamma-secretase. Assays for the NOTCH-1 mutations may be used diagnostically or as part of a treatment regimen for cancer patients.
    Type: Grant
    Filed: May 22, 2009
    Date of Patent: May 6, 2014
    Assignees: The Brigham and Women's Hospital, Inc., Dana-Farber Cancer Institute, Inc.
    Inventors: Jon C. Aster, Stephen C. Blacklow, A. Thomas Look, Adolfo A. Ferrando, Andrew P. Weng
  • Compositions Comprising Peroxyacid and Methods for Producing and Using the Same
    Publication number: 20140113000
    Abstract: The present invention provides methods for producing a non ?-keto peracid that has lower toxicity and lower corrosivity. The present embodiments also provide methods and compositions for reducing microbes on a surface, methods and compositions for preventing and reducing infectious vegetative bacteria on a substrate, and methods and compositions for treating a wound. In particular, compositions of the invention provide for a mixture of an ?-keto peracid and a non ?-keto peracid that works synergistically to reduce microbes on a surface, to prevent vegetative bacteria on a surface and to heal a wound in animals or humans.
    Type: Application
    Filed: October 18, 2013
    Publication date: April 24, 2014
    Applicant: CHD Bioscience, Inc.
    Inventors: Edwin D. Neas, John D. Skinner
  • Compositions and methods for the treatment of inflammation
    Patent number: 8673881
    Abstract: The invention relates to novel resolvin compounds and pharmaceutical preparations thereof. The invention further relates to methods of treatment using the novel resolvin compounds of the invention.
    Type: Grant
    Filed: April 13, 2010
    Date of Patent: March 18, 2014
    Assignee: A.T. Resolve Sarl
    Inventors: Per Gjorstrup, C. Eric Schwartz
  • Epoxide inhibitors of cysteine proteases
    Patent number: 8673904
    Abstract: Provided herein are novel epoxide inhibitors of cysteine proteases, compositions comprising the epoxide inhibitors, and packaged pharmaceuticals. Also provided are methods of inhibiting a papain-family cysteine protease and methods of treating or preventing a disease by administering a composition containing an epoxide inhibitor of the invention. The compositions may be administered in combination with another therapeutic agent.
    Type: Grant
    Filed: June 13, 2007
    Date of Patent: March 18, 2014
    Assignee: The Board of Trustees of the Leland Stanford Junior University
    Inventors: Matthew S. Bogyo, Amir M. Sadaghiani, Steven Verhelst
  • Derivatives of 4-nerolidylcatechol, pharmaceutical compositions comprising them and process for producing the same
    Patent number: 8673971
    Abstract: The present invention discloses 4-nerolidylcatechol and its derivatives isolated from South American/Amazon plants (Pothomorphe species) and their potential use as therapeutical agent for treatment of malarial symptoms, including malarial patients resistant to traditional drugs. The present invention also discloses a method for producing 4-nerolidylcatechol and their derivatives.
    Type: Grant
    Filed: December 28, 2007
    Date of Patent: March 18, 2014
    Assignee: Instituto Nacional de Pesquisa de Amazonia INPA
    Inventors: Ana Cristina Da Silva Pinto, Márcia Rúbia Silva Melo, Valter Ferreira De Andrade Neto, Francisco Célio Maia Chaves, Pedro Paulo Ribeiro Vieira, Adrian Martin Pohlit
  • Methods and composition for Treating Thyroid Hormone Related Disorders
    Publication number: 20140073691
    Abstract: The invention generally relates to methods of improving thyroid hormone sensitivity or treating a thyroid hormone resistance related disorder in a patient in need thereof, comprising administering a pharmaceutically effective amount of a MetAP-2 inhibitor. Such methods may include administering a MetAP-2 inhibitor at a dose that does not substantially modulate angiogenesis.
    Type: Application
    Filed: November 10, 2011
    Publication date: March 13, 2014
    Applicant: Zafgen, Inc.
    Inventor: Thomas E. Hughes
  • ANTIOXIDANT INFLAMMATION MODULATORS: C-17 HOMOLOGATED OLEANOLIC ACID DERIVATIVES
    Publication number: 20140066408
    Abstract: This invention provides, but is not limited to, novel oleanolic acid derivatives having the formula: wherein the variables are defined herein. Also provided are pharmaceutical compositions, kits and articles of manufacture comprising such compounds, methods and intermediates useful for making the compounds, and methods of using the compounds and compositions.
    Type: Application
    Filed: January 14, 2013
    Publication date: March 6, 2014
    Applicant: REATA PHARMACEUTICALS, INC.
    Inventor: REATA PHARMACEUTICALS, INC.
  • Expression Modulator For Clock Gene
    Publication number: 20140057979
    Abstract: The present invention provides substances that can be used in a broad range of applications and effectively regulate clock gene expression. Provided is a clock gene expression regulating agent comprising, as an active ingredient, one or more selected from the group consisting of caryophyllene oxide and compounds represented by the following structural formula: wherein X is CH3, NH2 or NHCH3.
    Type: Application
    Filed: October 15, 2013
    Publication date: February 27, 2014
    Applicant: Shiseido Company, Ltd.
    Inventors: Yoko Gozu, Shinichiro Haze
  • USE OF COMPOUNDS ISOLATED FROM EUPHORBIA NERIIFOLIA FOR TREATING CANCER AND/OR THROMBOCYTOPENIA
    Publication number: 20140056995
    Abstract: Novel Uses of small molecules, particularly, triterpenoids and ingol diterpenes isolated from Euphorbia neriifolia, are disclosed herein. The triterpenoids are useful as lead compounds for manufacturing a medicament or a pharmaceutical composition for treating cancer; whereas the ingol diterpenes are useful as lead compounds for manufacturing a medicament or a pharmaceutical composition for treating thrombocytopenia.
    Type: Application
    Filed: August 27, 2012
    Publication date: February 27, 2014
    Applicant: Mackay Memorial Hospital
    Inventors: YU-JEN CHEN, Lie-Chwn Lin, Ching-Pin Lin
  • Treatment of Obesity Using Non-Daily Administration of 6-O-(4-Dimethylaminoethoxy) Cinnamoyl Fumagillol
    Publication number: 20140051752
    Abstract: The invention generally relates to methods of treating an overweight or obese subject, and treating overweight- or obesity-related conditions using non-daily administration of e.g, a MetAP-2 inhibitor.
    Type: Application
    Filed: November 29, 2011
    Publication date: February 20, 2014
    Applicant: ZAFGEN, INC.
    Inventor: Thomas E. Hughes
  • Treatment of Obesity Using Non-Daily Administration of 6-O-(4-Dimethylaminoethoxy) Cinnamoyl Fumagillol
    Publication number: 20140045934
    Abstract: The invention generally relates to methods of treating an overweight or obese subject, and treating overweight- or obesity-related conditions using non-daily administration of e.g., a MetAP-2 inhibitor.
    Type: Application
    Filed: October 17, 2013
    Publication date: February 13, 2014
    Applicant: ZAFGEN, INC.
    Inventor: Thomas E. Hughes
  • Treatment of Obesity Using Non-Daily Administration of 6-O-(4-Dimethylaminoethoxy) Cinnamoyl Fumagillol
    Publication number: 20140045935
    Abstract: The invention generally relates to methods of treating an overweight or obese subject, and treating overweight- or obesity-related conditions using non-daily administration of e.g, a MetAP-2 inhibitor.
    Type: Application
    Filed: October 17, 2013
    Publication date: February 13, 2014
    Inventor: Thomas E. Hughes
  • Methods of treating an overweight or obese subject
    Patent number: 8642650
    Abstract: The invention generally relates to methods of treating an overweight or obese subject, and treating overweight- or obesity-related conditions. In certain embodiments, the invention provides a method of treating an overweight or obese subject including administering a MetAP2 inhibitor in which the amount administered does not substantially modulate angiogenesis.
    Type: Grant
    Filed: December 4, 2009
    Date of Patent: February 4, 2014
    Assignee: Zafgen, Inc.
    Inventors: Thomas E. Hughes, James E. Vath
  • Methods of Treating Obesity Using an Effective Dose of a METAP-2 Inhibitor
    Publication number: 20140011870
    Abstract: The invention generally relates to methods of treating an overweight or obese subject, and treating overweight- or obesity-related conditions using effective of amounts of a MetAP-2 inhibitor.
    Type: Application
    Filed: November 29, 2011
    Publication date: January 9, 2014
    Applicant: Zafgen, Inc.
    Inventor: Thomas E. Hughes
  • HONOKIOL ANALOGS AND THEIR USE IN TREATING CANCERS
    Publication number: 20130345302
    Abstract: Compounds, pharmaceutical compositions including the compounds, and methods of preparation and use thereof are disclosed. The compounds are honokiol analogs. The compounds and compositions can be used to treat and/or prevent a wide variety of cancers, including drug resistant cancers. Representative honokiol analogs include diepoxide honokiol analogues. The compounds are believed to function, at least, by inhibiting angiogenesis and/or inducing apoptosis. Thus, the compounds are novel therapeutic agents for a variety of cancers.
    Type: Application
    Filed: July 31, 2013
    Publication date: December 26, 2013
    Inventor: Jack L. Arbiser
  • CAROTENOID-CONTAINING COMPOSITION AND METHOD FOR PRODUCING THE SAME
    Publication number: 20130337024
    Abstract: Provided are a carotenoid-containing composition containing at least one carotenoid; at least one selected from the group consisting of ascorbic acid, derivatives thereof and salts of the acid and the derivatives; and an emulsifier, the at least one selected from the group consisting of ascorbic acid, derivatives thereof and salts of the acid and the derivatives being contained in an amount, in terms of a number of moles of ascorbic acid, in a range of from 30 times to 190 times a total number of moles of the at least one carotenoid, and the composition having a pH in the range of from 6.5 to 9.0; and a method for preparing the composition.
    Type: Application
    Filed: August 20, 2013
    Publication date: December 19, 2013
    Applicant: FUJIFILM Corporation
    Inventor: Shinichiro SERIZAWA
  • Fosfomycin pharmaceutical composition
    Patent number: 8604078
    Abstract: The present invention relates to a solid fosfomycin pharmaceutical composition stable in front the coloration, suitable for diabetics and not entailing gastrointestinal problems. The pharmaceutical composition of this invention comprises fosfomycin trometamol, glycine, and optionally other excipients as sucralose, silice dioxide, polyvinylpyrrolidone and flavor; and is substantially free from sugars and sugar alcohols as sucrose, fructose, glucose, xylitol, mannitol, sorbitol or mixtures thereof.
    Type: Grant
    Filed: March 19, 2012
    Date of Patent: December 10, 2013
    Inventor: Carlos Picornell Darder
  • Combination of epothilone analogs and chemotherapeutic agents for the treatment of proliferative diseases
    Patent number: 8598215
    Abstract: Compositions and methods are disclosed which are useful of the treatment and prevention of proliferative disorders.
    Type: Grant
    Filed: July 23, 2009
    Date of Patent: December 3, 2013
    Assignee: Bristol-Myers Squibb Company
    Inventor: Francis Y. F. Lee
  • Tiglien-3-one derivatives
    Patent number: 8598229
    Abstract: The present invention relates to tiglien-3-one compounds and their use in methods of treating or preventing protozoal infections, bacterial infections, parasitic infections and cell proliferative disorders. The tiglien-3-one compounds are also used in methods of controlling pests in humans, animals, plants and the environment.
    Type: Grant
    Filed: December 22, 2006
    Date of Patent: December 3, 2013
    Assignee: QBiotics Limited
    Inventors: Paul Warren Reddell, Victoria Anne Gordon
  • COMPOSITIONS AND METHODS FOR THE TREATMENT OF INFLAMMATORY DISEASE
    Publication number: 20130316989
    Abstract: The invention relates to methods of treating inflammatory disease comprising administering a compound of formula A, a compound of any one of formulae 1-49 or I-III, a lipoxin compound, or an oxylipin compound.
    Type: Application
    Filed: August 5, 2013
    Publication date: November 28, 2013
    Applicant: RESOLVYX PHARMACEUTICALS, INC.
    Inventor: Per Gjorstrup
  • Methods of Reducing Risk of Hepatobiliary Dysfunction During Rapid Weight Loss with METAP-2 Inhibitors
    Publication number: 20130316994
    Abstract: The invention generally relates in part to methods of reducing hepatobiliary dysfunction and reducing risk of incident hepatobiliary dysfunction, comprising administering a MetAP2 inhibitor to patients in need thereof. The invention also relates in part to methods of effecting weight loss while reducing hepatic injury or risk thereof, comprising administering a MetAP2 inhibitor.
    Type: Application
    Filed: November 29, 2011
    Publication date: November 28, 2013
    Applicant: Zafgen, Inc.
    Inventor: Thomas E. Hughes
  • O-NITRO COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS INCLUDING SAME
    Publication number: 20130309324
    Abstract: The present invention provides O-nitro compounds, pharmaceutical compositions of O-nitro compounds and methods of using O-nitro compounds and/or pharmaceutical compositions thereof to treat or prevent diseases or disorders characterized by abnormal cell proliferation, such as cancer, inflammation, cardiovascular disease and autoimmune disease.
    Type: Application
    Filed: July 26, 2013
    Publication date: November 21, 2013
    Applicants: RadioRx, Inc., c/o Interwest Venture Partners, Alliant Techsystems Inc.
    Inventors: Mark D. Bednarski, Susan Knox, Louis F. Cannizzo, Kristin F. Warner, Robert B. Wardle, Stephen P. Velarde, Shoucheng Ning
  • TRICYCLIC LACTONES FOR TREATMENT OF CANCER
    Publication number: 20130310451
    Abstract: The present invention discloses novel compounds useful for the inhibition of IL-6/STAT signaling and/or PI3K/NF-?B signaling in the treatment of associated diseases or conditions, e.g. cancer. A pharmaceutical composition comprising such novel compounds, its use and a method thereof, is also disclosed.
    Type: Application
    Filed: July 18, 2011
    Publication date: November 21, 2013
    Applicant: GLACTONE PHARMA DEVELOPMENT AB
    Inventors: Ritha Gidlöf, Martin Johansson, Olov Sterner, Eduardo Muñoz
  • Honokiol analogs and their use in treating cancers
    Patent number: 8586627
    Abstract: Compounds, pharmaceutical compositions including the compounds, and methods of preparation and use thereof are disclosed. The compounds are honokiol analogs. The compounds and compositions can be used to treat and/or prevent a wide variety of cancers, including drug resistant cancers. Representative honokiol analogs include diepoxide honokiol analogues. The compounds are believed to function, at least, by inhibiting angiogenesis and/or inducing apoptosis. Thus, the compounds are novel therapeutic agents for a variety of cancers.
    Type: Grant
    Filed: April 29, 2008
    Date of Patent: November 19, 2013
    Inventor: Jack L. Arbiser
  • COMPOSITIONS AND METHODS TO IMPROVE THE THERAPEUTIC BENEFIT OF SUBOPTIMALLY ADMINISTERED CHEMICAL COMPOUNDS INCLUDING SUBSTITUTED HEXITOLS SUCH AS DIANHYDROGALACTITOL AND DIACETYLDIANHYDROGALACTITOL
    Publication number: 20130289107
    Abstract: The present invention describes methods and compositions for improving the therapeutic efficacy of therapeutic agents previously limited by suboptimal therapeutic performance by either improving efficacy as monotherapy or reducing side effects. Such methods and compositions are particularly applicable to substituted hexitols such as dianhydrogalactitol and diacetyldianhydrogalactitol.
    Type: Application
    Filed: August 17, 2011
    Publication date: October 31, 2013
    Applicant: DEL MAR PHARMACEUTICALS
    Inventor: Dennis M. Brown
  • Combination of epothilone analogs and chemotherapeutic agents for the treatment of proliferative diseases
    Patent number: 8569347
    Abstract: Compositions and methods are disclosed which are useful of the treatment and prevention of proliferative disorders.
    Type: Grant
    Filed: May 20, 2004
    Date of Patent: October 29, 2013
    Assignee: Bristol-Myers Squibb Company
    Inventor: Francis Y. F. Lee
  • MEDICAMENT FOR LCT POISONING
    Publication number: 20130280286
    Abstract: The medicament for the prevention or the relief of poisoning by large clostridial cytotoxins (LCTs), in particular Clostridium difficile toxins A and B (TcdA and TcdB), is characterized by containing as active ingredient at least one effector, namely an inhibitor or activator of the autocatalytic protease activity of LCTs (large clostridial cytotoxins).
    Type: Application
    Filed: May 30, 2012
    Publication date: October 24, 2013
    Applicant: JOHANNES GUTENBERG-UNIVERSITAET MAINZ
    Inventors: Christoph VON EICHEL-STREIBER, Jessica REINEKE, Stefan TENZER, Hansjörg SCHILD, Maja RUPNIK
  • NOVEL ANTI-INFLAMMATORY METABOLITE DERIVED FROM OMEGA-3-TYPE FATTY ACID
    Publication number: 20130274327
    Abstract: The purpose is to provide a compound which can overcomes the disadvantages of conventional steroid drugs and NSAID. It is found that specific epoxy monohydroxy forms of eicosapentaenoic acid, docosahexaenoic acid and docosapentaenoic acid which are independently represented by formulae [chemical formula 1], [chemical formula 5] and the like have an inhibitory activity on neutrophils. This compound can inhibit the invasion of neutrophils into tissues and the activation of neutrophils which are observed in acute inflammations.
    Type: Application
    Filed: August 4, 2011
    Publication date: October 17, 2013
    Inventors: Makoto Arita, Hiroyuki Arai, Yosuke Isobe, Tadafumi Kubota
  • METHODS OF TREATING AN OVERWEIGHT SUBJECT
    Publication number: 20130266578
    Abstract: The invention generally relates in part to methods of effecting weight loss and/or improving glucose tolerance in a patient in need thereof, comprising administering a MetAP2 inhibitor.
    Type: Application
    Filed: April 7, 2011
    Publication date: October 10, 2013
    Inventors: Thomas E. Hughes, James E. Vath, Alan D. Cherrington
  • Fatty Acid Inhibitors
    Publication number: 20130261099
    Abstract: Fatty acid inhibitors, pharmaceutical compositions including fatty acid inhibitors, methods for using fatty acid inhibitors to treat a variety of diseases, and methods for preparing fatty acid inhibitors are provided herein.
    Type: Application
    Filed: May 24, 2013
    Publication date: October 3, 2013
    Applicant: LIFE TECHNOLOGIES CORPORATION
    Inventor: Bruce BRANCHAUD
  • Methods for enhancing hematopoietic progenitor cell engraftment
    Patent number: 8546382
    Abstract: Described herein are methods for improving engraftment of hematopoietic cells in an individual following hematopoietic progenitor cell transplantation (e.g., via bone marrow or cord blood transplantation). Methods for increasing hematopoietic progenitor cell proliferation in individuals with bone marrow aplasia are also described. The methods involve administering an agent that inhibits adipogenesis, adipocyte growth, adipocyte differentiation and/or adipocyte proliferation.
    Type: Grant
    Filed: April 15, 2010
    Date of Patent: October 1, 2013
    Assignee: Children's Medical Center Corporation
    Inventors: Olaia Naveiras, George Daley, Pamela L. Wenzel
  • NEURONAL CIRCUIT-DEPENDENT NEUROPROTECTION BY INTERACTION BETWEEN NICOTINIC RECEPTORS
    Publication number: 20130237560
    Abstract: A method of inhibiting excitotoxicity by indirectly activating ?4?2 nicotinic acetylcholine receptors (nAChRs) which indirectly activate synaptic AMPA and NMDA receptors is disclosed. Inhibitors of ?7 nACHRs, such as macrocyclic diterpenoids, more specifically cembranoids or methyllycaconitine (MLA), indirectly activate ?4?2 nAChRs and can be used to treat neurodegenerative diseases, including, but not limited to, Alzheimer's Disease, Parkinson Disease, AIDS related dementia and the delayed effects of stroke. They can also be used to treat diseases associated with neuronal impairment, including, but not limited to glaucoma caused by optical nerve damage, delayed effects of epilepsy; and multiple sclerosis.
    Type: Application
    Filed: March 15, 2013
    Publication date: September 12, 2013
    Inventors: Peter Andrew Ferchmin, Vesna Ana Eterovic De Ferchmin, Hector Manuel Maldonado
  • VIRAL INHIBITOR COMPOSITIONS FOR IN VIVO THERAPEUTIC USE COMPRISING A COMBINATION OF (-) -CARVONE, GERANIOL AND A FURTHER ESSENTIAL OIL COMPONENT
    Publication number: 20130225676
    Abstract: The present invention concerns an antiviral composition comprising the following components: R-(?)-2-methyl-5-(prop-1-en-2-yl)-cyclohex-2-enone (also called (?) carvone) and S-(+)-2-methyl-5-(prop-1-en-2-yl)-cyclohex-2-enone (also called (+) carvone) and (2E)-3,7-dimethylocta-2,6-dien-1-ol (also called trans-geraniol) in combination with at least one more component chosen among essential oils components for use in treatment and prevention of diseases caused by DNA enveloped viruses, DNA non-enveloped viruses, RNA enveloped viruses and RNA non-enveloped viruses.
    Type: Application
    Filed: March 28, 2011
    Publication date: August 29, 2013
    Inventor: Christine Coppens
  • Reducing nephropathy with inhibitors of soluble epoxide hydrolase and epoxyeicosanoids
    Patent number: 8513302
    Abstract: The invention provides uses and methods for reducing nephropathy in persons with diabetes mellitus (particularly Type 2 diabetes), in persons with metabolic syndrome, in persons with triglyceride levels over 215 mg/dL, and in persons with a cholesterol level over 200 mg/dL, by administering an inhibitor of soluble epoxide hydrolase (“sEH”). Optionally, a cis-epoxyeicosantrienoic acid (“EET”) can be administered with the sEH inhibitor. The invention further provides for using EETs in conjunction with one or more sEH inhibitors to reduce hypertension, and for compositions of EETs coated with a material insoluble in an acid of pH 3 but soluble in a solution with a pH of 7.4 or higher.
    Type: Grant
    Filed: May 4, 2011
    Date of Patent: August 20, 2013
    Assignee: The Regents of the University of California
    Inventors: Bruce D. Hammock, Takaho Watanabe, Seung-Jin Ma, Susan E. Bennett, Judith S. Stern, Christophe Morisseau, In-Hae Kim
  • METHODS AND COMPOSITIONS FOR MALIC ENZYME 2 (ME2) AS A TARGET FOR CANCER THERAPY
    Publication number: 20130209488
    Abstract: The present invention relates to methods, compositions, and diagnostic tests for treating and diagnosing cancer and other related diseases that result in dysregulation of malic enzyme 2. In particular, the methods and compositions include combination therapy, such as with a combination of two or more ME2 inhibitors or a combination of an ME2 inhibitor and an anticancer agent.
    Type: Application
    Filed: August 5, 2011
    Publication date: August 15, 2013
    Applicant: BETH ISRAEL DEACONESS MEDICAL CENTER, INC
    Inventors: Vikas P. Sukhatme, Jian-Guo Ren
  • Use Of 2,5-Dihydroxybenzene Derivatives For Treating Actinic Keratosis
    Publication number: 20130202580
    Abstract: The present invention relates to the use of a 2,5-dihydroxybenzene derivative represented by Formula (I) or a pharmaceutically acceptable salt, solvate, isomer, or prodrug thereof for the therapeutic and/or prophylactic treatment of, inter alia, actinic keratosis.
    Type: Application
    Filed: February 14, 2013
    Publication date: August 8, 2013
    Applicant: AmDerma Pharmaceuticals, LLC
    Inventor: AmDerma Pharmaceuticals, LLC
  • Crystalline Solids of a METAP-2 Inhibitor and Methods of Making and Using Same
    Publication number: 20130197078
    Abstract: The disclosure is in part directed to crystalline forms of 6-O-(4-dimethylaminoethoxy)cinnamoyl fumagillol and variants thereof.
    Type: Application
    Filed: November 16, 2012
    Publication date: August 1, 2013
    Inventors: Thomas Crawford, Hayley A. Reece
  • Use of fucoxanthin in the preparation of product for improving memory and having neuroprotective effect associated with neurodegenerative disorder
    Publication number: 20130189382
    Abstract: Use of fucoxanthin in the preparation of a product having neuroprotective effect associated with neurodegenerative disorder and improving memory is disclosed in the disclosure. A product having neuroprotective effect associated with neurodegenerative disorder is also disclosed in the disclosure. Fucoxanthin can inhibit oxidative stress of cells and has the effect of preventing or treating Alzheimer's disease and improving memory.
    Type: Application
    Filed: September 30, 2010
    Publication date: July 25, 2013
    Applicant: Beijing Gingko Group Biological Technology Co., Ltd.
    Inventors: Yanmei Li, Liang Li
  • Uses of sesquiterpene derivatives
    Patent number: 8481592
    Abstract: The present invention relates to a pharmaceutical composition for preventing or treating hyperlipidemia, fatty liver, diabetes and obesity comprising a sesquiterpene derivative as an active ingredient. The sesquiterpene derivatives of the present invention leads to decrease in body fat weight, visceral fat weight and total cholesterol levels, triglyceride of plasma and liver tissue, blood glucose and blood insulin levels in a fast state, finally exhibiting efficacies on prevention or treatment of hyperlipidemia, fatty liver, diabetes and obesity.
    Type: Grant
    Filed: October 20, 2008
    Date of Patent: July 9, 2013
    Assignee: Kwang Dong Pharm Co., Ltd.
    Inventors: Tae-Sun Park, Ha-Won Kim
  • Inhibition of Cancer Cell Proliferation Using Oleoylethanolamide
    Publication number: 20130172407
    Abstract: A pharmaceutical composition including oleoylethanolamide (OEA) is administered to inhibit tumor/cancer cell proliferation. The pharmaceutically composition may additionally include vitamin A, carotenoids, ?-3 polyunsaturated fatty acid, ?-6 polyunsaturated fatty acid and/or conjugated linolenic acid. The tumor/cancer may be colorectal cancer, lung adenocarcinoma, breast cancer, hepatoma, oral cancer and/or stomach adenocarcinoma.
    Type: Application
    Filed: November 6, 2012
    Publication date: July 4, 2013
    Applicant: China Medical University
    Inventor: China Medical University
  • NEURONAL CIRCUIT-DEPENDENT NEUROPROTECTION BY INTERACTION BETWEEN NICOTINIC RECEPTORS
    Publication number: 20130165495
    Abstract: A method of inhibiting excitotoxicity by indirectly activating ?4?2 nicotinic acetylcholine receptors (nAChRs) which indirectly activate synaptic AMPA and NMDA receptors is disclosed Inhibitors of ?7 nACHRs, such as macrocyclic diterpenoids, more specifically cembranoids or methyllycaconitine (MLA), indirectly activate ?4?2 nAChRs and can be used to treat neurodegenerative diseases, including, but not limited to, Alzheimer's Disease, Parkinson Disease, AIDS related dementia and the delayed effects of stroke. They can also be used to treat diseases associated with neuronal impairment, including, but not limited to glaucoma caused by optical nerve damage, delayed effects of epilepsy; and multiple sclerosis.
    Type: Application
    Filed: November 9, 2012
    Publication date: June 27, 2013
    Inventors: Peter Andrew Ferchmin, Vesna Ana Eterovic De Ferchmin, Hector Manuel Maldonado, Khalid El Sayed
  • Fatty acid inhibitors
    Patent number: 8470879
    Abstract: Fatty acid inhibitors, pharmaceutical compositions including fatty acid inhibitors, methods for using fatty acid inhibitors to treat a variety of diseases, and methods for preparing fatty acid inhibitors are provided herein.
    Type: Grant
    Filed: November 2, 2010
    Date of Patent: June 25, 2013
    Assignee: Life Technologies Corporation
    Inventor: Bruce Branchaud
  • BIOCOMPATIBLE BIODEGRADABLE FUMAGILLIN ANALOG CONJUGATES
    Publication number: 20130158046
    Abstract: Fumagillin analog polymer conjugates, methods of making fumagillin analog polymer conjugates, compositions comprising a polymer conjugate of a fumagillin analog, and methods for treating cancer, or treating angiogenic diseases comprising administering to a subject in need thereof an effective amount of a polymer conjugate of a fumagillin analog, are described. Also described are novel fumagillin analogs, methods of making fumagillin analogs, compositions comprising at least one fumagillin analog, and methods for treating cancer, or treating angiogenic diseases comprising administering to a subject in need thereof an effective amount of a fumagillin analog.
    Type: Application
    Filed: February 15, 2013
    Publication date: June 20, 2013
    Applicant: Mersana Therapeutics, Inc
    Inventors: Laura C. Akullian, Russell C. Petter, John J. Kane, Charles E. Hammond, Mao Yin, Aleksandr Yurkovetskiy, Cheri A. Stevenson